Clinical Trials Logo

Hyperkeratosis, Epidermolytic clinical trials

View clinical trials related to Hyperkeratosis, Epidermolytic.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03041038 Completed - Netherton Syndrome Clinical Trials

The Efficacy and Safety of Secukinumab in Patients With Ichthyoses

Start date: December 2016
Phase: Phase 2
Study type: Interventional

The ichthyoses are a group of lifelong genetic disorders which share characteristics of generalized skin thickening, scaling and underlying cutaneous inflammation. There are no therapies based on growing understanding of what causes the disease. However, there have been recent discoveries of marked elevations in expression of interleukin-17A (IL-17A) and IL-17-related cytokines in the skin of individuals with ichthyosis, which may explain the inflammation. Investigators propose that IL-17-targeting therapeutics will safely suppress the inflammation and possibly the other features of ichthyosis, improving quality of life.

NCT ID: NCT00074685 Completed - Ichthyosis Clinical Trials

National Registry for Ichthyosis and Related Disorders

Start date: September 1994
Phase:
Study type: Observational

The ichthyoses are a family of genetic skin diseases characterized by dry, thickened, scaling skin. Dermatologists estimate that there are over twenty varieties of ichthyosis, with a wide range of severity and associated symptoms. This registry is designed to identify people in the United States with the ichthyoses and other related disorders and to collect information about their skin ailment and how it has affected them. The database is available for review by approved research applicants. The registry is confidential and provides investigators a way to share information about studies and trials with potential participants while maintaining participants' privacy. Although the Registry is closed to new enrollment, it is still maintained in order to provide information related to understanding the diagnosis, pathophysiology, and treatment of ichthyoses. Support for studies continues and inquiries from investigators are welcomed.